Report library

MedTech analysis
Special bundles
Strategy analysis
Strategy analysis
Disease analysis
Company analysis
Drug analysis
MedTech analysis

Sort by Custom

Click to order products ascending

Display 15 Products per page

UK Healthcare System Overview

$2,995.00

Reform of the NHS is underway despite widespread controversy and opposition from physicians, and will necessitate a change in the way pharmaceutical companies work with key stakeholders.
November 2, 2016
Find out more
UK Regulatory Issues

$2,995.00

Recently there have been several new regulatory changes in the UK aimed at reducing the regulatory burden and allowing earlier access to medicines which are seen as a positive development for the pharmaceutical industry.
November 2, 2016
Find out more
Ularitide
Read More
Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

added clinical value and benefit on survival.
March 16, 2016
Find out more
Ulcerative Colitis (UC) KOL Interview – UK

$599.00

A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.
March 1, 2021
Find out more
Ultibro
Read More
Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.
April 11, 2016
Find out more
umbralisib
Read More
Umbralisib (TG Therapeutics/Rhizen) is a novel phosphoinositide 3-kinase (PI3K) delta inhibitor that also selectively inhibits casein kinase-1 (CK1) epsilon. Expression of the PI3K delta isoform plays a role in B-cell development and function, and is often overactivated in B-cell malignancies.
January 30, 2019
Find out more
United Kingdom, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure

$1,995.00

This report presents the disease incidence and prevalence and surgical procedure volumes for selected neurological diseases/disorders and procedures in the United Kingdom (U.K.); incidence and prevalence figures are compared with those of the Benelux countries
December 3, 2012
Find out more
United Kingdom, Surgical Procedure Volumes

$4,850.00

This report presents an overview of selected medical specialties and the number of surgical procedures performed for selected diseases/disorders in the European Union member state of the U.K.
September 22, 2016
Find out more
United States, Cardiovascular Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the UnitedStates (U.S.) as well as the surgical procedure volumes for selected cardiovascular/thoracic diseases/disorders.
January 1, 2013
Find out more
United States, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected musculoskeletal diseases/disorders.
January 1, 2013
Find out more
United States, Neurological Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

$1,995.00

This report presents the prevalence and number of hospital discharges in the United States (U.S.) as well as the surgical procedure volumes for selected neurological diseases/disorders.
January 1, 2013
Find out more
Upadacitinib
Read More
Upadacitinib (AbbVie) is an oral small molecule inhibitor of Janus kinase (JAK)-1 that is being developed in several indications including Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and ulcerative colitis.
August 2, 2018
Find out more
Uptravi
Read More
Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.
October 29, 2018
Find out more
US Healthcare System Overview

$2,995.00

Continued growth in healthcare expenditure and the high number of individuals without health insurance coverage were the key drivers of the passage of the healthcare reform law.
November 2, 2016
Find out more
US Image-Guided Surgical Neuronavigation and EBRT Systems Market

$3,750.00

The US image-guided surgical (IGS) neuronavigation and external beam radiation therapy (EBRT) systems market totaled more than $284m in 2015.
October 31, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Call Back

Name

Email *

Company name *

Phone number *